These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 27725595)

  • 21. The molecular basis and clinical significance of genetic mutations identified in myelodysplastic syndromes.
    Zhang L; Padron E; Lancet J
    Leuk Res; 2015 Jan; 39(1):6-17. PubMed ID: 25465125
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Chromosomal Aberrations in Myelodysplastic Syndromes].
    Ru X; Zhang LY; Li Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Oct; 23(5):1509-12. PubMed ID: 26524067
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of chromosome alterations, genetic mutations and clonal hematopoiesis of indeterminate potential (CHIP) on the classification and risk stratification of MDS.
    Ganguly BB; Banerjee D; Agarwal MB
    Blood Cells Mol Dis; 2018 Mar; 69():90-100. PubMed ID: 29079134
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Reprogramming technology reveals genetic and functional diversity of subclones in myelodysplastic syndromes].
    Chonabayashi K; Yoshida Y; Takaori-Kondo A
    Rinsho Ketsueki; 2017; 58(7):787-791. PubMed ID: 28781275
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetics of myelodysplastic syndromes: new insights.
    Graubert T; Walter MJ
    Hematology Am Soc Hematol Educ Program; 2011; 2011():543-9. PubMed ID: 22160087
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular Pathogenesis of MDS.
    Look AT
    Hematology Am Soc Hematol Educ Program; 2005; ():156-60. PubMed ID: 16304374
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cytogenetic evaluation of mesenchymal stem/stromal cells from patients with myelodysplastic syndromes at different time-points during ex vivo expansion.
    Kouvidi E; Stratigi A; Batsali A; Mavroudi I; Mastrodemou S; Ximeri M; Papadaki HA; Pontikoglou CG
    Leuk Res; 2016 Apr; 43():24-32. PubMed ID: 26930455
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular pathways in myelodysplastic syndromes and acute myeloid leukemia: relationships and distinctions-a review.
    Bernasconi P
    Br J Haematol; 2008 Sep; 142(5):695-708. PubMed ID: 18540941
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Sequential acquisition of mutations in myelodysplastic syndromes].
    Makishima H
    Rinsho Ketsueki; 2017; 58(10):1828-1837. PubMed ID: 28978821
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MDS/AML-associated cytogenetic abnormalities in multiple myeloma and monoclonal gammopathy of undetermined significance: evidence for frequent de novo occurrence and multipotent stem cell involvement of del(20q).
    Nilsson T; Nilsson L; Lenhoff S; Rylander L; Astrand-Grundström I; Strömbeck B; Höglund M; Turesson I; Westin J; Mitelman F; Jacobsen SE; Johansson B
    Genes Chromosomes Cancer; 2004 Nov; 41(3):223-31. PubMed ID: 15334545
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases.
    Ok CY; Patel KP; Garcia-Manero G; Routbort MJ; Fu B; Tang G; Goswami M; Singh R; Kanagal-Shamanna R; Pierce SA; Young KH; Kantarjian HM; Medeiros LJ; Luthra R; Wang SA
    Leuk Res; 2015 Mar; 39(3):348-54. PubMed ID: 25573287
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mechanisms underlying the heterogeneity of myelodysplastic syndromes.
    Dussiau C; Fontenay M
    Exp Hematol; 2018 Feb; 58():17-26. PubMed ID: 29175473
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Understanding the pathogenesis of myelodysplastic syndromes.
    Delforge M
    Hematol J; 2003; 4(5):303-9. PubMed ID: 14502253
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular Pathogenesis and Treatment of Myelodysplastic Syndromes.
    Nakajima H
    Intern Med; 2021 Jan; 60(1):15-23. PubMed ID: 32009100
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recent advances in understanding the molecular pathogenesis of myelodysplastic syndromes.
    Kulasekararaj AG; Mohamedali AM; Mufti GJ
    Br J Haematol; 2013 Sep; 162(5):587-605. PubMed ID: 23869491
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular genetic features of myelodysplastic syndromes (MDS).
    Willman CL
    Leukemia; 1998 Sep; 12 Suppl 1():S2-6. PubMed ID: 9777886
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetic pathways in the pathogenesis of therapy-related myelodysplasia and acute myeloid leukemia.
    Pedersen-Bjergaard J; Andersen MT; Andersen MK
    Hematology Am Soc Hematol Educ Program; 2007; ():392-7. PubMed ID: 18024656
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Usefulness of classic cytogenetic testing compared to fluorescence in situ hybridization in genetic diagnosis of 58 patients with myelodysplastic syndromes.
    Skonieczka K; Duszeńko E; Wyrowińska E; Haus O
    Pol Arch Med Wewn; 2009 Jun; 119(6):366-72. PubMed ID: 19694218
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The genetics of the myelodysplastic syndromes: classical cytogenetics and recent molecular insights.
    Cherian S; Bagg A
    Hematology; 2006 Feb; 11(1):1-13. PubMed ID: 16522543
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alternative genetic pathways and cooperating genetic abnormalities in the pathogenesis of therapy-related myelodysplasia and acute myeloid leukemia.
    Pedersen-Bjergaard J; Christiansen DH; Desta F; Andersen MK
    Leukemia; 2006 Nov; 20(11):1943-9. PubMed ID: 16990778
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.